Table Graph
   

remdesivir - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.75 [0.54, 1.03]< 10%4 studies (4/-)96.4 %some concernnot evaluable moderatecrucial-
deaths 0.88 [0.68, 1.14]< 127%7 studies (7/-)84.0 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.75 [0.50, 1.12]< 152%4 studies (4/-)92.2 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.95 [0.55, 1.64]< 10%1 study (1/-)57.3 %NAnot evaluable important-
clinical improvement 1.29 [1.16, 1.44]> 10%5 studies (5/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.17 [0.74, 1.85]> 173%4 studies (4/-)75.2 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.45 [1.18, 1.79]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.00 [0.70, 1.43]> 148%4 studies (4/-)50.8 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.23 [1.12, 1.35]> 10%5 studies (5/-)100.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.97 [0.85, 1.10]< 10%1 study (1/-)67.8 %NAnot evaluable important-
mechanical ventilation 0.87 [0.39, 1.96]< 129%4 studies (4/-)63.1 %some concernnot evaluable moderateimportant-
recovery 1.17 [1.03, 1.33]> 10%3 studies (3/-)99.2 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
serious adverse events 0.67 [0.53, 0.85]< 10%4 studies (4/-)99.9 %some concernnot evaluable moderateimportant-
adverse events 1.40 [1.05, 1.87]< 14%2 studies (2/-)1.0 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.62 [0.23, 1.64]< 10%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.58 [0.34, 0.97]< 16%2 studies (2/-)98.1 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.97 [0.48, 1.93]< 10%2 studies (2/-)53.8 %lownot evaluable highnon important-
pulmonary embolism 0.82 [0.20, 3.29]< 10%2 studies (2/-)61.1 %some concernnot evaluable moderatenon important-
renal impairment 1.02 [0.64, 1.61]< 10%2 studies (2/-)47.2 %some concernnot evaluable moderatenon important-
serious adverse events (SAE), any 1.98 [1.27, 3.11]< 10%1 study (1/-)0.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons